1 Introduction Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 30% of adults in the western world [1]. MASLD results from fat accumulation in the liver without excessive alcohol consumption and is considered a manifestation of metabolic syndrome in the liver [2]. MASLD encompasses a spectrum of conditions, ranging from simple hepatic steatosis (HS) to steatohepatitis (MASH), early fibrosis, liver cirrhosis, and hepatocellular carcinoma (HCC) [3].
